Introduction
This quiz collection on Post-marketing reporting & lifecycle management is designed for M.Pharm students to strengthen their knowledge of regulatory pharmacovigilance and product lifecycle activities. The questions focus on real-world post-authorization responsibilities: safety surveillance, periodic reporting, signal detection, risk management planning, post-approval changes and lifecycle strategies. Each item highlights core guidelines, report types, stakeholders and standard practices used by Marketing Authorization Holders and regulators. Use these MCQs to test conceptual understanding and to prepare for practical documentation and regulatory writing tasks required in pharmaceutical practice and submissions.
Q1. What is the primary objective of post-marketing reporting?
- To support marketing campaigns in new regions
- To ensure ongoing monitoring of product safety and benefit–risk in the real-world setting
- To replace clinical trial data for initial approval
- To reduce manufacturing costs
Correct Answer: To ensure ongoing monitoring of product safety and benefit–risk in the real-world setting
Q2. Which ICH guideline specifically defines the Periodic Benefit-Risk Evaluation Report (PBRER)?
- ICH E2A
- ICH E2C(R2)
- ICH E2B(R3)
- ICH Q9
Correct Answer: ICH E2C(R2)
Q3. What does DSUR stand for in the context of safety reporting?
- Drug Safety Update Report
- Development Safety Update Report
- Daily Safety Urgent Report
- Drug Surveillance Unified Record
Correct Answer: Development Safety Update Report
Q4. Which periodic report is commonly used in the United States to summarize adverse drug experiences periodically?
- PSUR
- PADER
- PBRER
- DSUR
Correct Answer: PADER
Q5. Post-marketing clinical studies that further define safety and effectiveness are typically classified as which phase?
- Phase I
- Phase II
- Phase III
- Phase IV
Correct Answer: Phase IV
Q6. What is meant by ‘signal detection’ in pharmacovigilance?
- The process of advertising new therapeutic uses
- The identification of a new or changed causal association between a drug and an adverse event based on data sources
- Manufacturing trend analysis
- Approval of a new generic competitor
Correct Answer: The identification of a new or changed causal association between a drug and an adverse event based on data sources
Q7. The Risk Management Plan (RMP) is intended to do which of the following?
- Outline pricing strategies across markets
- Describe identified and potential risks and planned pharmacovigilance and risk minimization activities
- Detail clinical trial protocols for Phase I healthy volunteers
- Replace the need for periodic safety reports
Correct Answer: Describe identified and potential risks and planned pharmacovigilance and risk minimization activities
Q8. Expedited reporting in the post-marketing setting typically refers to which action?
- Annual compilation of all adverse events
- Rapid notification to regulators of serious, unexpected adverse drug reactions
- Delayed publication of safety findings after 12 months
- Marketing notifications to prescribers
Correct Answer: Rapid notification to regulators of serious, unexpected adverse drug reactions
Q9. ICH E2B(R3) primarily addresses which topic?
- Guidance for benefit–risk assessment methodology
- Electronic standards for individual case safety reports (ICSRs)
- Quality risk management for manufacturing
- Clinical trial safety reporting timelines
Correct Answer: Electronic standards for individual case safety reports (ICSRs)
Q10. CIOMS forms are used for which purpose?
- Financial reporting to regulatory agencies
- Standardized reporting of individual adverse drug reaction cases between industry and regulators
- Label translation templates
- Clinical site monitoring checklists
Correct Answer: Standardized reporting of individual adverse drug reaction cases between industry and regulators
Q11. The PBRER replaced which earlier periodic safety document in many regions?
- DSUR
- PSUR
- PADER
- RMP
Correct Answer: PSUR
Q12. Which of the following is an example of lifecycle management for a marketed product?
- Obtaining a first marketing authorization in the first country
- Line extension such as a new formulation or new indication
- Closing a clinical development program without submission
- Discontinuing manufacturing due to low demand
Correct Answer: Line extension such as a new formulation or new indication
Q13. Which category of post-approval change typically requires prior regulatory approval before implementation?
- Minor change
- Administrative change
- Major change
- Editorial change
Correct Answer: Major change
Q14. Pharmacoepidemiology primarily studies what?
- Mechanisms of drug action at molecular level
- Drug effects and usage patterns in large populations
- Formulation development techniques
- Preclinical toxicology in animals
Correct Answer: Drug effects and usage patterns in large populations
Q15. Which report is mainly intended to integrate cumulative safety information and evaluate benefit–risk periodically?
- Investigator’s Brochure
- Periodic Benefit–Risk Evaluation Report (PBRER)
- Case Safety Report
- Marketing Authorization Application (MAA)
Correct Answer: Periodic Benefit–Risk Evaluation Report (PBRER)
Q16. When a potential safety signal is detected, the first regulatory-pharmacovigilance action should be which of the following?
- Immediate market withdrawal
- Signal validation and in-depth causality assessment
- Publication of a press release blaming prescribers
- Ignore until multiple media reports appear
Correct Answer: Signal validation and in-depth causality assessment
Q17. Which elements are commonly included in risk minimization measures within an RMP?
- Routine pharmacovigilance only
- Educational materials for healthcare professionals, restricted distribution, and targeted monitoring
- Manufacturing cost reductions
- Advertising to increase usage
Correct Answer: Educational materials for healthcare professionals, restricted distribution, and targeted monitoring
Q18. In regulatory language MAH means what?
- Medical Authorization Board
- Market Access Heuristic
- Marketing Authorization Holder
- Mandatory Audit Handbook
Correct Answer: Marketing Authorization Holder
Q19. PASS in post-authorization monitoring stands for which of the following?
- Post-Approval Safety Summary
- Post-Authorization Safety Study
- Periodic Annual Safety Statement
- Primary Adverse event Surveillance System
Correct Answer: Post-Authorization Safety Study
Q20. Which of the following are primary data sources for post-marketing surveillance?
- Spontaneous adverse event reports
- Published literature and electronic healthcare records
- Targeted post-authorization safety studies and registries
- All of the above
Correct Answer: All of the above
